Answers are grounded in this paper and cite their sources.
The long‐anticipated VICTOR study (reported in this issue of American Journal of Transplantation) represents the first large, randomized, multicenter trial of valganciclovir versus IV ganciclovir for treatment of cytomegalovirus (CMV) viremia (1). Valganciclovir, an oral valine ester of ganciclovir (2), has been previously shown to be efficacious for prophylaxis of CMV infection after solid organ transplantation (3,4). Unlike the previous formulation of oral ganciclovir, which had poor bioavailability, oral valganciclovir achieves higher serum levels (2).
No takes yet. Share an insight, caveat, or question.
Robin K. Avery (2007) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: